Guangzhou Health Start Pharmaceutical Technology

Guangzhou Health-Start Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in Guangzhou, China, specializing in the development of therapeutic vaccines for infectious diseases. The company's primary focus is on addressing chronic hepatitis B (CHB) through its lead candidate, HS-101, a recombinant therapeutic vaccine designed to stimulate the immune system to clear the virus. Health-Start's research and development efforts are centered on creating innovative biologics that offer potential functional cures for long-term viral infections. The company operates within the Guangzhou biopharmaceutical cluster and maintains a pipeline of immunotherapeutic candidates at various stages of development. By leveraging its proprietary recombinant protein platform, Health-Start aims to provide effective treatment options for patients with limited therapeutic alternatives.